ArticleQuantitative imaging in medicine and surgery2021
A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles.
Article in Quantitative imaging in medicine and surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS).International journal of surgery (London, England) · 2026Guideline
- Contrast-enhanced ultrasound findings are associated with tumor viability and depth of response in selected patients with unresectable hepatocellular carcinoma treated with immunotherapy-based combination therapy.Journal of medical ultrasonics (2001) · 2026Article
- Systematic evaluation and meta-analysis of the diagnostic accuracy of ultrasound contrast in predicting the efficacy of systemic therapy for advanced hepatocellular carcinoma.Translational cancer research · 2026Article
- Association of week-2 Contrast-Enhanced Ultrasound Perfusion Changes with Response to Lenvatinib Plus PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study.Journal of hepatocellular carcinoma · 2026Article
- Noninvasive Visualization of Tumor Blood Vessels within Hepatocellular Carcinoma by Application of Superb Microvascular Imaging to Contrast-Enhanced Ultrasonography.Diagnostics (Basel, Switzerland) · 2024Article
- Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2023Article
- Associations between tumor grade, contrast-enhanced ultrasound features, and microvascular density in patients with clear cell renal cell carcinoma: a retrospective study.Quantitative imaging in medicine and surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contrast-enhanced computed tomography (CECT) is generally used to evaluate the response to treatment of hepatocellular carcinoma (HCC); however, CECT is unsuitable for the early prediction of therapeutic effects and frequent monitoring. We aimed to investigate the usefulness of our simplified method for the quantification of tumor vascularity using contrast-enhanced ultrasound (CEUS) with perfluorobutane microbubbles [Sonazoid
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.